• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    7/6/22 5:39:43 PM ET
    $ACRX
    $ADGI
    $ADVM
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • AcelRx Pharmaceuticals (NASDAQ:ACRX) stock increased by 38.9% to $0.36 during Wednesday's after-market session. AcelRx Pharmaceuticals's trading volume hit 4.7 million shares by close, accounting for 336.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $52.9 million.
    • Clearside Biomedical (NASDAQ:CLSD) stock rose 14.17% to $1.61. The market value of their outstanding shares is at $96.8 million.
    • Quotient (NASDAQ:QTNT) stock increased by 8.43% to $0.27. Today's trading volume for this security ended up closing at 3.7 million shares, which is 242.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $36.6 million.
    • Agile Therapeutics (NASDAQ:AGRX) stock rose 8.42% to $0.74. Trading volume for this security closed at 3.2 million, accounting for 21.2% of its average full-day volume over the last 100 days. The company's market cap stands at $3.3 million.
    • Qualigen Therapeutics (NASDAQ:QLGN) shares increased by 7.89% to $0.54. The company's market cap stands at $20.9 million.
    • Stealth BioTherapeutics (NASDAQ:MITO) stock rose 7.88% to $0.24. The market value of their outstanding shares is at $17.5 million.

    Losers

    • CytomX Therapeutics (NASDAQ:CTMX) shares decreased by 28.9% to $1.4 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 811.9K shares, which is 74.4 percent of its average volume over the last 100 days. The company's market cap stands at $91.5 million.
    • Vor Biopharma (NASDAQ:VOR) shares declined by 10.99% to $4.54. The market value of their outstanding shares is at $170.6 million.
    • Titan Pharmaceuticals (NASDAQ:TTNP) stock decreased by 8.91% to $0.82. Today's trading volume for this security ended up closing at 437.3K shares, which is 92.4 percent of its average volume over the last 100 days. The company's market cap stands at $11.9 million.
    • SomaLogic (NASDAQ:SLGC) stock fell 6.91% to $4.45. The company's market cap stands at $811.1 million.
    • Adagio Therapeutics (NASDAQ:ADGI) stock decreased by 6.09% to $3.55. The market value of their outstanding shares is at $389.5 million.
    • Adverum Biotechnologies (NASDAQ:ADVM) stock declined by 5.7% to $1.16. The company's market cap stands at $114.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $ADGI
    $ADVM
    $AGRX

    CompanyDatePrice TargetRatingAnalyst
    Vor Biopharma Inc.
    $VOR
    3/30/2026$50.00Buy
    Jefferies
    Vor Biopharma Inc.
    $VOR
    3/19/2026$30.00Overweight
    Wells Fargo
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Vor Biopharma Inc.
    $VOR
    1/9/2026$50.00Buy
    Citigroup
    Vor Biopharma Inc.
    $VOR
    12/17/2025Buy
    TD Cowen
    Vor Biopharma Inc.
    $VOR
    12/9/2025$43.00Overweight
    Analyst
    Vor Biopharma Inc.
    $VOR
    11/25/2025$9.00Neutral
    Wedbush
    More analyst ratings

    $ACRX
    $ADGI
    $ADVM
    $AGRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 9,050 shares of Vor Bio's common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Induc

    4/1/26 5:00:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical development Pro-forma cash and investment balance of $530.2 million as of December 31, 2025 expected to provide runway into early 2029 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. "Over the past six months, Vor Bio repositioned the compa

    3/30/26 8:01:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

    BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating telitacicept in adult patients with active primary Sjögren's disease (SjD), formerly known as Sjögren's syndrome. "Dosing the first patient in the global Phase 3 UPSTREAM SjD trial represents a significant milestone for telitacicept and for patients living with Sjögren's disease. As the only BAFF/APRIL inhibitor currently in Phase 3 development for this condition, we believe telitacicept has th

    3/30/26 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $ADGI
    $ADVM
    $AGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ra Capital Management, L.P.

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    4/6/26 6:51:05 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Tcg Crossover Gp Ii, Llc

    3 - Vor Biopharma Inc. (0001817229) (Issuer)

    4/1/26 5:15:53 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chu Yu-Waye

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:41:25 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADGI
    $ADVM
    $AGRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Vor Biopharma Inc.

    SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

    4/1/26 5:09:55 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Vor Biopharma Inc.

    S-8 - Vor Biopharma Inc. (0001817229) (Filer)

    3/30/26 8:06:55 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Vor Biopharma Inc.

    10-K - Vor Biopharma Inc. (0001817229) (Filer)

    3/30/26 8:03:04 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $ADGI
    $ADVM
    $AGRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ACRX
    $ADGI
    $ADVM
    $AGRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ACRX
    $ADGI
    $ADVM
    $AGRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Jefferies initiated coverage on Vor Biopharma with a new price target

    Jefferies initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $50.00

    3/30/26 8:22:03 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo initiated coverage on Vor Biopharma with a new price target

    Wells Fargo initiated coverage of Vor Biopharma with a rating of Overweight and set a new price target of $30.00

    3/19/26 8:27:43 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO, PRESIDENT AND DIRECTOR Fischer Laurent bought $553,917 worth of shares (128,699 units at $4.30), increasing direct ownership by 177% to 201,513 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:06 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF OPERATING OFFICER Soparkar Peter bought $211,000 worth of shares (50,000 units at $4.22), increasing direct ownership by 166% to 80,189 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:04 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

    4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    4/28/25 3:31:52 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADGI
    $ADVM
    $AGRX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

    BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's recently announced $150M PIPE financing, which included participation from both investors. "Andrew and Wouter bring highly complementary experience in life sciences investment, financing strategy, and board-level oversight. We are delighted to welcome them to our Board at an important moment for the

    12/23/25 4:01:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

    BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development to the company's leadership team. "We are thrilled to welcome Jeremy to Vor Bio," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "His deep clinical expertise as a rheumatologist, coupled with his strong track record in industry and as a thought leader in autoimmune and inflammato

    11/3/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $ADGI
    $ADVM
    $AGRX
    Financials

    Live finance-specific insights

    View All

    CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

    - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M

    3/16/26 7:05:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

    - Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) - - Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Conference call on Monday, March 16 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics

    3/16/26 7:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to

    3/4/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADGI
    $ADVM
    $AGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 6:57:12 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 6:40:56 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    11/14/24 4:33:50 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care